Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.7K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.1K
Adult Stem Cells01:33

Adult Stem Cells

33.8K
Stem cells are undifferentiated cells that divide and produce more stem cells or progenitor cells that differentiate into mature, specialized cell types. All the cells in the body are generated from stem cells in the early embryo, but small populations of stem cells are also present in many adult tissues including the bone marrow, brain, skin, and gut. These adult stem cells typically produce the various cell types found in that tissue—to replace cells that are damaged or to continuously...
33.8K
Embryonic Stem Cells00:58

Embryonic Stem Cells

32.4K
Embryonic stem (ES) cells are undifferentiated pluripotent cells, meaning they can produce any cell type in the body. This gives them tremendous potential in science and medicine since they can generate specific cell types for use in research or to replace body cells lost due to damage or disease.
32.4K
Embryonic Stem Cells00:57

Embryonic Stem Cells

5.0K
Embryonic stem (ES) cells were first discovered in mice in 1981 by Martin Evans. In 1998, James Thomson identified a method to isolate embryonic stem cells from humans. Human embryonic stem cells (hESCs) are obtained from 3-5 day old embryos that remain unused after an in vitro fertilization procedure.
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...
5.0K
Induced Pluripotent Stem Cells01:13

Induced Pluripotent Stem Cells

28.0K
Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore...
28.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of Tacrolimus-induced thrombotic microangiopathy in a heart transplant recipient: Utilizing novel immunosuppression strategies.

JHLT open·2026
Same author

Hemodynamic-guided V-A ECMO management for cardiogenic shock: Insight from initial experience from TWEET study (to wean an ECMO trials).

Perfusion·2026
Same author

Left Ventricular Venting Strategies for Cardiogenic Shock in Patients Treated With Extracorporeal Cardiopulmonary Support V-A ECMO: From Left Ventricular Unloading to Offloading.

The American journal of cardiology·2026
Same author

Belatacept as an Emerging Option in Immunosuppression-Induced Thrombotic Microangiopathy After Heart Transplantation.

JACC. Case reports·2026
Same author

Therapeutic Plasma Exchange for Uncontrollable Bleeding After Platelet Inhibition with Ticagrelor: A Report of 2 Cases.

The American journal of case reports·2026
Same author

Multimodality Assessment of a Culprit LAD Myocardial Bridge in a Patient With Congenital Heart Disease.

JACC. Case reports·2026

Related Experiment Video

Updated: Jan 29, 2026

In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.2K

Stem Cell and Left Ventricular Assist Device Combination Therapy.

Gregor Poglajen1,2, Igor D Gregoric2, Rajko Radovancevic2

  • 1Advanced Heart Failure and Transplantation Center, University Medical Center Ljubljana, Slovenia (G.P., B.V.).

Circulation. Heart Failure
|February 15, 2019
PubMed
Summary

Ventricular assist devices (VADs) and cell therapy show potential for heart failure recovery. Combining these treatments may enhance myocardial repair more effectively than using them alone.

Keywords:
assisted circulationheart failurestem cells

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.1K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

9.9K

Related Experiment Videos

Last Updated: Jan 29, 2026

In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.2K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.1K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

9.9K

Area of Science:

  • Cardiovascular Medicine
  • Regenerative Medicine
  • Biomedical Engineering

Background:

  • Ventricular assist devices (VADs) are crucial for advanced chronic heart failure.
  • VAD support can lead to myocardial structural and functional improvements.
  • Significant discrepancies exist between structural and functional recovery in VAD patients.

Purpose of the Study:

  • To review the effects of VADs and cell therapy on myocardial reverse remodeling.
  • To explore the potential benefits of combining VAD support with cell therapy.
  • To discuss the rationale for a combined strategy to promote heart muscle recovery.

Main Methods:

  • Literature review of VAD technology and cell therapy in heart failure.
  • Analysis of studies on myocardial reverse remodeling.
  • Discussion of combined therapeutic approaches.

Main Results:

  • VADs can induce reverse remodeling, but functional recovery is often limited.
  • Cell therapy shows promise for augmenting myocardial repair in heart failure.
  • The combination of VADs and cell therapy is largely unexplored but theoretically advantageous.

Conclusions:

  • Further research is needed to evaluate the combined efficacy of VADs and cell therapy.
  • A combined approach may offer enhanced myocardial recovery for heart failure patients.
  • This strategy holds potential for improving long-term outcomes in advanced heart failure.